Albertsons Swings to 4Q Loss on Charge From Opioid Settlement

Dow Jones

Apr 14

By Nicholas G. Miller

Albertsons swung to a fourth-quarter loss fueled by a charge from a new opioid settlement set to resolve substantially all opioid-related claims brought against the company.

The company reported a loss of $480.8 million, or 94 cents a share, compared with a profit of $171.8 million, or 29 cents a share, the year prior.

The loss included a $600 million charge related to the opioid settlement framework. On Tuesday, the company said it reached a $774 million settlement to resolve opioid-related claims brought against the company nationally.

The company has faced lawsuits accusing its pharmacy of allegedly failing to prevent the overuse of opioids.

The payments will be made over the course of nine years.

For the fourth quarter, adjusted earnings were 48 cents a share. Analysts polled by FactSet expected 44 cents a share.

Net sales and other revenue rose to $20.25 billion from $18.8 billion. Wall Street expected $20.47 billion.

Identical sales rose 0.7%. Analysts forecast 1.7%.

The company guided for fiscal 2026 identical sales of flat to up 1% and adjusted earnings of $2.22 to $2.32 a share. Analysts see fiscal-year identical sales growth of 1.2% and adjusted earnings of $2.27 a share.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

April 14, 2026 07:59 ET (11:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2627944558"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627944558\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627944558?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627944558","market":"sh","top_or_hot":-1,"title":"Albertsons Swings to 4Q Loss on Charge From Opioid Settlement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Albertsons swung to a fourth-quarter loss fueled by a charge from a new opioid settlement set to resolve substantially all opioid-related claims brought against the company. \n</p>\n<p>\n  The company reported a loss of $480.8 million, or 94 cents a share, compared with a profit of $171.8 million, or 29 cents a share, the year prior. \n</p>\n<p>\n  The loss included a $600 million charge related to the opioid settlement framework. On Tuesday, the company said it reached a $774 million settlement  to resolve opioid-related claims brought against the company nationally. \n</p>\n<p>\n  The company has faced lawsuits accusing its pharmacy of allegedly failing to prevent the overuse of opioids. \n</p>\n<p>\n  The payments will be made over the course of nine years. \n</p>\n<p>\n  For the fourth quarter, adjusted earnings were 48 cents a share. Analysts polled by FactSet expected 44 cents a share. \n</p>\n<p>\n  Net sales and other revenue rose to $20.25 billion from $18.8 billion. Wall Street expected $20.47 billion. \n</p>\n<p>\n  Identical sales rose 0.7%. Analysts forecast 1.7%. \n</p>\n<p>\n  The company guided for fiscal 2026 identical sales of flat to up 1% and adjusted earnings of $2.22 to $2.32 a share. Analysts see fiscal-year identical sales growth of 1.2% and adjusted earnings of $2.27 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 07:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Albertsons Swings to 4Q Loss on Charge From Opioid Settlement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlbertsons Swings to 4Q Loss on Charge From Opioid Settlement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-14 19:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Albertsons swung to a fourth-quarter loss fueled by a charge from a new opioid settlement set to resolve substantially all opioid-related claims brought against the company. \n</p>\n<p>\n  The company reported a loss of $480.8 million, or 94 cents a share, compared with a profit of $171.8 million, or 29 cents a share, the year prior. \n</p>\n<p>\n  The loss included a $600 million charge related to the opioid settlement framework. On Tuesday, the company said it reached a $774 million settlement  to resolve opioid-related claims brought against the company nationally. \n</p>\n<p>\n  The company has faced lawsuits accusing its pharmacy of allegedly failing to prevent the overuse of opioids. \n</p>\n<p>\n  The payments will be made over the course of nine years. \n</p>\n<p>\n  For the fourth quarter, adjusted earnings were 48 cents a share. Analysts polled by FactSet expected 44 cents a share. \n</p>\n<p>\n  Net sales and other revenue rose to $20.25 billion from $18.8 billion. Wall Street expected $20.47 billion. \n</p>\n<p>\n  Identical sales rose 0.7%. Analysts forecast 1.7%. \n</p>\n<p>\n  The company guided for fiscal 2026 identical sales of flat to up 1% and adjusted earnings of $2.22 to $2.32 a share. Analysts see fiscal-year identical sales growth of 1.2% and adjusted earnings of $2.27 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 07:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4113","symbol_name":"食品零售","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627944558","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627944558","pubTimestamp":1776167940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Albertsons swung to a fourth-quarter loss fueled by a charge from a new opioid settlement set to resolve substantially all opioid-related claims brought against the company.The company reported a loss of $480.8 million, or 94 cents a share, compared with a profit of $171.8 million, or 29 cents a share, the year prior.The loss included a $600 million charge related to the opioid settlement framework. On Tuesday, the company said it reached a $774 million settlement  to resolve opioid-related claims brought against the company nationally.The company has faced lawsuits accusing its pharmacy of allegedly failing to prevent the overuse of opioids.The payments will be made over the course of nine years.For the fourth quarter, adjusted earnings were 48 cents a share. Analysts polled by FactSet expected 44 cents a share.Net sales and other revenue rose to $20.25 billion from $18.8 billion. Wall Street expected $20.47 billion.The company guided for fiscal 2026 identical sales of flat to up 1% a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4113":"食品零售","ACI":"艾伯森"},"translate_title":"艾伯森因阿片类药物和解指控而陷入第四季度亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACI":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Albertsons swung to a fourth-quarter loss fueled by a charge from a new opioid settlement set to resolve substantially all opioid-related claims brought against the company. \n\n\n  The company reported a loss of $480.8 million, or 94 cents a share, compared with a profit of $171.8 million, or 29 cents a share, the year prior. \n\n\n  The loss included a $600 million charge related to the opioid settlement framework. On Tuesday, the company said it reached a $774 million settlement  to resolve opioid-related claims brought against the company nationally. \n\n\n  The company has faced lawsuits accusing its pharmacy of allegedly failing to prevent the overuse of opioids. \n\n\n  The payments will be made over the course of nine years. \n\n\n  For the fourth quarter, adjusted earnings were 48 cents a share. Analysts polled by FactSet expected 44 cents a share. \n\n\n  Net sales and other revenue rose to $20.25 billion from $18.8 billion. Wall Street expected $20.47 billion. \n\n\n  Identical sales rose 0.7%. Analysts forecast 1.7%. \n\n\n  The company guided for fiscal 2026 identical sales of flat to up 1% and adjusted earnings of $2.22 to $2.32 a share. Analysts see fiscal-year identical sales growth of 1.2% and adjusted earnings of $2.27 a share. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 07:59 ET (11:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}